- Migraine sufferers got some relief from US regulators who approved the first of a new class of drugs for migraine prevention.
- The United States Food and Drug Administration said it endorsed Aimovig for prevention of migraine in adults, through monthly self-injections.
- Aimovig is the first in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule involved in migraine attacks, the FDA said in a statement.
- Migraine is three times more common in women than in men and affects more than 10 per cent of people worldwide.
What is Migraine?
- A migraine is a primary headache disorder characterized by recurrent headaches that are moderate to severe. Typically, the headaches affect one half of the head, are pulsating in nature, and last from two to 72 hours. Associated symptoms may include nausea, vomiting, and sensitivity to light, sound, or smell.